Cargando…
Soluplus-Mediated Diosgenin Amorphous Solid Dispersion with High Solubility and High Stability: Development, Characterization and Oral Bioavailability
BACKGROUND AND PURPOSE: The traditional Chinese medicine, diosgenin (Dio), has attracted increasing attention because it possesses various therapeutic effects, including anti-tumor, anti-infective and anti-allergic properties. However, the commercial application of Dio is limited by its extremely lo...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396739/ https://www.ncbi.nlm.nih.gov/pubmed/32801637 http://dx.doi.org/10.2147/DDDT.S253405 |
_version_ | 1783565652325302272 |
---|---|
author | Liu, Pei Zhou, Jian-yu Chang, Jin-hua Liu, Xi-gang Xue, He-fei Wang, Ru-xing Li, Zhong-si Li, Chun-shi Wang, Jian Liu, Cui-zhe |
author_facet | Liu, Pei Zhou, Jian-yu Chang, Jin-hua Liu, Xi-gang Xue, He-fei Wang, Ru-xing Li, Zhong-si Li, Chun-shi Wang, Jian Liu, Cui-zhe |
author_sort | Liu, Pei |
collection | PubMed |
description | BACKGROUND AND PURPOSE: The traditional Chinese medicine, diosgenin (Dio), has attracted increasing attention because it possesses various therapeutic effects, including anti-tumor, anti-infective and anti-allergic properties. However, the commercial application of Dio is limited by its extremely low aqueous solubility and inferior bioavailability in vivo. Soluplus, a novel excipient, has great solubilization and capacity of crystallization inhibition. The purpose of this study was to prepare Soluplus-mediated Dio amorphous solid dispersions (ASDs) to improve its solubility, bioavailability and stability. METHODS: The crystallization inhibition studies were firstly carried out to select excipients using a solvent shift method. According to solubility and dissolution results, the preparation methods and the ratios of drug to excipient were further optimized. The interaction between Dio and Soluplus was characterized by differential scanning calorimetry (DSC), fourier transform infrared (FT-IR) spectroscopy, scanning electron microscopy (SEM), powder X-ray diffraction (PXRD) and molecular docking. The pharmacokinetic study was conducted to explore the potential of Dio ASDs for oral administration. Furthermore, the long-term stability of Dio ASDs was also investigated. RESULTS: Soluplus was preliminarily selected from various excipients because of its potential to improve solubility and stability. The optimized ASDs significantly improved the aqueous solubility of Dio due to its amorphization and the molecular interactions between Dio and Soluplus, as evidenced by dissolution test in vitro, DSC, FT-IR spectroscopy, SEM, PXRD and molecular docking technique. Furthermore, pharmacokinetic studies in rats revealed that the bioavailability of Dio from ASDs was improved about 5 times. In addition, Dio ASDs were stable when stored at 40°C and 75% humidity for 6 months. CONCLUSION: These results indicated that Dio ASDs, with its high solubility, high bioavailability and high stability, would open a promising way in pharmaceutical applications. |
format | Online Article Text |
id | pubmed-7396739 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-73967392020-08-13 Soluplus-Mediated Diosgenin Amorphous Solid Dispersion with High Solubility and High Stability: Development, Characterization and Oral Bioavailability Liu, Pei Zhou, Jian-yu Chang, Jin-hua Liu, Xi-gang Xue, He-fei Wang, Ru-xing Li, Zhong-si Li, Chun-shi Wang, Jian Liu, Cui-zhe Drug Des Devel Ther Original Research BACKGROUND AND PURPOSE: The traditional Chinese medicine, diosgenin (Dio), has attracted increasing attention because it possesses various therapeutic effects, including anti-tumor, anti-infective and anti-allergic properties. However, the commercial application of Dio is limited by its extremely low aqueous solubility and inferior bioavailability in vivo. Soluplus, a novel excipient, has great solubilization and capacity of crystallization inhibition. The purpose of this study was to prepare Soluplus-mediated Dio amorphous solid dispersions (ASDs) to improve its solubility, bioavailability and stability. METHODS: The crystallization inhibition studies were firstly carried out to select excipients using a solvent shift method. According to solubility and dissolution results, the preparation methods and the ratios of drug to excipient were further optimized. The interaction between Dio and Soluplus was characterized by differential scanning calorimetry (DSC), fourier transform infrared (FT-IR) spectroscopy, scanning electron microscopy (SEM), powder X-ray diffraction (PXRD) and molecular docking. The pharmacokinetic study was conducted to explore the potential of Dio ASDs for oral administration. Furthermore, the long-term stability of Dio ASDs was also investigated. RESULTS: Soluplus was preliminarily selected from various excipients because of its potential to improve solubility and stability. The optimized ASDs significantly improved the aqueous solubility of Dio due to its amorphization and the molecular interactions between Dio and Soluplus, as evidenced by dissolution test in vitro, DSC, FT-IR spectroscopy, SEM, PXRD and molecular docking technique. Furthermore, pharmacokinetic studies in rats revealed that the bioavailability of Dio from ASDs was improved about 5 times. In addition, Dio ASDs were stable when stored at 40°C and 75% humidity for 6 months. CONCLUSION: These results indicated that Dio ASDs, with its high solubility, high bioavailability and high stability, would open a promising way in pharmaceutical applications. Dove 2020-07-27 /pmc/articles/PMC7396739/ /pubmed/32801637 http://dx.doi.org/10.2147/DDDT.S253405 Text en © 2020 Liu et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Liu, Pei Zhou, Jian-yu Chang, Jin-hua Liu, Xi-gang Xue, He-fei Wang, Ru-xing Li, Zhong-si Li, Chun-shi Wang, Jian Liu, Cui-zhe Soluplus-Mediated Diosgenin Amorphous Solid Dispersion with High Solubility and High Stability: Development, Characterization and Oral Bioavailability |
title | Soluplus-Mediated Diosgenin Amorphous Solid Dispersion with High Solubility and High Stability: Development, Characterization and Oral Bioavailability |
title_full | Soluplus-Mediated Diosgenin Amorphous Solid Dispersion with High Solubility and High Stability: Development, Characterization and Oral Bioavailability |
title_fullStr | Soluplus-Mediated Diosgenin Amorphous Solid Dispersion with High Solubility and High Stability: Development, Characterization and Oral Bioavailability |
title_full_unstemmed | Soluplus-Mediated Diosgenin Amorphous Solid Dispersion with High Solubility and High Stability: Development, Characterization and Oral Bioavailability |
title_short | Soluplus-Mediated Diosgenin Amorphous Solid Dispersion with High Solubility and High Stability: Development, Characterization and Oral Bioavailability |
title_sort | soluplus-mediated diosgenin amorphous solid dispersion with high solubility and high stability: development, characterization and oral bioavailability |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396739/ https://www.ncbi.nlm.nih.gov/pubmed/32801637 http://dx.doi.org/10.2147/DDDT.S253405 |
work_keys_str_mv | AT liupei soluplusmediateddiosgeninamorphoussoliddispersionwithhighsolubilityandhighstabilitydevelopmentcharacterizationandoralbioavailability AT zhoujianyu soluplusmediateddiosgeninamorphoussoliddispersionwithhighsolubilityandhighstabilitydevelopmentcharacterizationandoralbioavailability AT changjinhua soluplusmediateddiosgeninamorphoussoliddispersionwithhighsolubilityandhighstabilitydevelopmentcharacterizationandoralbioavailability AT liuxigang soluplusmediateddiosgeninamorphoussoliddispersionwithhighsolubilityandhighstabilitydevelopmentcharacterizationandoralbioavailability AT xuehefei soluplusmediateddiosgeninamorphoussoliddispersionwithhighsolubilityandhighstabilitydevelopmentcharacterizationandoralbioavailability AT wangruxing soluplusmediateddiosgeninamorphoussoliddispersionwithhighsolubilityandhighstabilitydevelopmentcharacterizationandoralbioavailability AT lizhongsi soluplusmediateddiosgeninamorphoussoliddispersionwithhighsolubilityandhighstabilitydevelopmentcharacterizationandoralbioavailability AT lichunshi soluplusmediateddiosgeninamorphoussoliddispersionwithhighsolubilityandhighstabilitydevelopmentcharacterizationandoralbioavailability AT wangjian soluplusmediateddiosgeninamorphoussoliddispersionwithhighsolubilityandhighstabilitydevelopmentcharacterizationandoralbioavailability AT liucuizhe soluplusmediateddiosgeninamorphoussoliddispersionwithhighsolubilityandhighstabilitydevelopmentcharacterizationandoralbioavailability |